Skip to main content
Caplight Logo









Neurocentrx Pharma

Neurocentrx Pharma

Private
EdinburghHealthcare & Life Scienceshttps://www.neurocentrx.com/

Last Round

Seed

Sep 23, 2025

Total Funding Raised

$5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Neurocentrx Pharma is a biopharmaceutical company developing oral ketamine formulations designed to treat patients with mood disorders and other neurological conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Mental Health, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

ketamine therapyabuse-deterrent formulationhome-based caretreatment-resistant depressionpsychedelic medicinedigital prescription safetyrisk evaluation and mitigation strategyREMSbiopharmaceuticalmental health techdrug-plus-softwareclinical-stage pharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurocentrx Pharma Comparables

Compare Neurocentrx Pharma with similar companies based on industry and business-model similarity.

Neurocentrx Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tasman Therapeutics
88%
HMNC Brain Health
85%
AtaiBeckley Inc.
79%

Neurocentrx Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 23, 2025
Series ASep 23, 2025
VC RoundMay 12, 2022
AngelMar 20, 2014

Key People

Founding team and executive leadership

Jeff Roix

Chief Executive Officer

Executive Team

Neurocentrx Pharma Investors

Notable investors and investment history

Neurocentrx Pharma investors
InvestorRounds
o2h venturesVC Round
Equity GapVC Round, Angel
Meltwind AdvisoryVC Round
Old College CapitalVC Round
Neo Kuma VenturesVC Round
Scottish Investment Bank (Scottish Enterprise)VC Round
Wellcome TrustSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 163% MoM, reaching 1.5K.

Neurocentrx Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neurocentrx Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neurocentrx Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersEdinburgh
Employee Range7
Year Founded2013
Last FundingSep 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?